Determination of neurometabolism in patients with mild and moderate cognitive impairments

Objective: to estimate the diagnostic value of neuropower mapping (NPM) and positron emission tomography (PET) and their relationships in the evaluation of neurometabolism in patients with predementia cognitive impairments.Material and methods. The investigation enrolled 125 patients with clinical s...

Full description

Bibliographic Details
Main Authors: N. N. Mikheev, M. V. Zharikova, L. V. Eliseeva, Yu. V. Borisova
Format: Article
Language:English
Published: Luchevaya Diagnostika, LLC 2016-02-01
Series:Вестник рентгенологии и радиологии
Subjects:
Online Access:https://www.russianradiology.ru/jour/article/view/12
_version_ 1797341689196576768
author N. N. Mikheev
M. V. Zharikova
L. V. Eliseeva
Yu. V. Borisova
author_facet N. N. Mikheev
M. V. Zharikova
L. V. Eliseeva
Yu. V. Borisova
author_sort N. N. Mikheev
collection DOAJ
description Objective: to estimate the diagnostic value of neuropower mapping (NPM) and positron emission tomography (PET) and their relationships in the evaluation of neurometabolism in patients with predementia cognitive impairments.Material and methods. The investigation enrolled 125 patients with clinical signs of cognitive impairments. The patients were divided into 4 groups: 1) predementia cognitive impairments (PCI) in the presence of cerebrovascular disease (CVD); 2) PCI in the presence of  psychoautonomic syndrome (PAS); 3) PCI in the presence of sequels to acute cerebrovascular accident (SCVA); 4) PCI in the presence of toxic, dysmetabolic, hypoxic encephalopathies (TDHEP). All the patients underwent NPM and 55 patients had PET.Results and discussion. NPM and PET revealed neurometabolic disturbances in 100 and 46,3% of cases, respectively. The sensitivity of NPM was significantly higher than that of PET. The highest number of diffuse and diffuse-focal hypometabolism cases (n = 19 (63,3%)) were seen in the CVD and SCVA groups.Conclusion. 1. NPM and PET assess two aspects of brain  neurometabolism. 2. PET hypometabolism characterizes either structural organic abnormalities in the brain in the presence SCVA or initial manifestations of the neurodegenerative process. 3. NPM  readings characterize the activity, strength of metabolic responses, that is to say, cerebral reactivity. 4. PET readings are important in determining the prognosis of disease and NPM ones are essential in defining drug treatment policy.
first_indexed 2024-03-08T10:22:39Z
format Article
id doaj.art-5ef0d4c05f374a9a9bf6b940254c8b0d
institution Directory Open Access Journal
issn 0042-4676
2619-0478
language English
last_indexed 2024-03-08T10:22:39Z
publishDate 2016-02-01
publisher Luchevaya Diagnostika, LLC
record_format Article
series Вестник рентгенологии и радиологии
spelling doaj.art-5ef0d4c05f374a9a9bf6b940254c8b0d2024-01-27T18:38:32ZengLuchevaya Diagnostika, LLCВестник рентгенологии и радиологии0042-46762619-04782016-02-0102152210.20862/0042-4676-2015-0-2-15-2212Determination of neurometabolism in patients with mild and moderate cognitive impairmentsN. N. Mikheev0M. V. Zharikova1L. V. Eliseeva2Yu. V. Borisova3Main Clinical Hospital, Russian Ministry of InteriorMain Clinical Hospital, Russian Ministry of InteriorMain Clinical Hospital, Russian Ministry of InteriorClinical Hospital № 1, Department for Presidential Affairs of the Russian FederationObjective: to estimate the diagnostic value of neuropower mapping (NPM) and positron emission tomography (PET) and their relationships in the evaluation of neurometabolism in patients with predementia cognitive impairments.Material and methods. The investigation enrolled 125 patients with clinical signs of cognitive impairments. The patients were divided into 4 groups: 1) predementia cognitive impairments (PCI) in the presence of cerebrovascular disease (CVD); 2) PCI in the presence of  psychoautonomic syndrome (PAS); 3) PCI in the presence of sequels to acute cerebrovascular accident (SCVA); 4) PCI in the presence of toxic, dysmetabolic, hypoxic encephalopathies (TDHEP). All the patients underwent NPM and 55 patients had PET.Results and discussion. NPM and PET revealed neurometabolic disturbances in 100 and 46,3% of cases, respectively. The sensitivity of NPM was significantly higher than that of PET. The highest number of diffuse and diffuse-focal hypometabolism cases (n = 19 (63,3%)) were seen in the CVD and SCVA groups.Conclusion. 1. NPM and PET assess two aspects of brain  neurometabolism. 2. PET hypometabolism characterizes either structural organic abnormalities in the brain in the presence SCVA or initial manifestations of the neurodegenerative process. 3. NPM  readings characterize the activity, strength of metabolic responses, that is to say, cerebral reactivity. 4. PET readings are important in determining the prognosis of disease and NPM ones are essential in defining drug treatment policy.https://www.russianradiology.ru/jour/article/view/12neuropower mappingpositron emission tomographycognitive impairmentsneurometabolism
spellingShingle N. N. Mikheev
M. V. Zharikova
L. V. Eliseeva
Yu. V. Borisova
Determination of neurometabolism in patients with mild and moderate cognitive impairments
Вестник рентгенологии и радиологии
neuropower mapping
positron emission tomography
cognitive impairments
neurometabolism
title Determination of neurometabolism in patients with mild and moderate cognitive impairments
title_full Determination of neurometabolism in patients with mild and moderate cognitive impairments
title_fullStr Determination of neurometabolism in patients with mild and moderate cognitive impairments
title_full_unstemmed Determination of neurometabolism in patients with mild and moderate cognitive impairments
title_short Determination of neurometabolism in patients with mild and moderate cognitive impairments
title_sort determination of neurometabolism in patients with mild and moderate cognitive impairments
topic neuropower mapping
positron emission tomography
cognitive impairments
neurometabolism
url https://www.russianradiology.ru/jour/article/view/12
work_keys_str_mv AT nnmikheev determinationofneurometabolisminpatientswithmildandmoderatecognitiveimpairments
AT mvzharikova determinationofneurometabolisminpatientswithmildandmoderatecognitiveimpairments
AT lveliseeva determinationofneurometabolisminpatientswithmildandmoderatecognitiveimpairments
AT yuvborisova determinationofneurometabolisminpatientswithmildandmoderatecognitiveimpairments